33 reports

  • 11 BY APPLICATION

In 2013, around ##. ## million people in the US either lived with or were in remission from lymphoma, leukemia, or myeloma.

  • Point Of Care Testing
  • North America
  • United States
  • Alere Inc.
  • Danaher Corporation
  • Introduction

Leukemia, lymphoma, and myeloma accounted for ##. ##% of the estimated ##, ##, ## new cancer cases.

  • Point Of Care Testing
  • World
  • Becton Property Group
  • Millipore Corporation
  • Thermo Fisher Scientific, Inc.
  • BECKMAN COULTER

It also launched the anaplastic lymphoma kinase test in Europe as a companion diagnostic test for lung cancer.

  • Point Of Care Testing
  • Europe
  • Beckman Coulter, Inc.
  • Roche Group
  • Thermo Fisher Scientific, Inc.

On October ##, 2012, the company launched the anaplastic lymphoma kinase (ALK) test in Europe as a companion diagnostic test to aid in identifying individuals who need lung cancer therapy.

  • Point Of Care Testing
  • World
  • Alere Inc.
  • DiaSorin S.p.A.
  • Roche Group

It provides rapid POC test that detects HIV-##/ ## antibodies and free HIV-## p## antigen.

  • Point Of Care Testing
  • World
  • Alere Inc.
  • DiaSorin S.p.A.
  • Roche Group

Title Page No. ##.

  • Point Of Care Testing
  • World
  • Abbott
  • ARKRAY, Inc.
  • Bayer AG

Alere Determine HIV ##-## Ag/ Ab Combo was approved in August 2013; it provides rapid POC test that detects HIV-##/ ## antibodies and free HIV-## p## antigen.

  • Point Of Care Testing
  • Europe
  • Market Size
  • Alere Inc.
  • Roche Group

Alere Determine HIV ##-## Ag/ Ab Combo was approved in August 2013, and it provides rapid POC test that detects HIV-##/ ## antibodies and free HIV-## p## antigen.

  • In Vitro Diagnostics
  • Point Of Care Testing
  • United States
  • Alere Inc.
  • Beckman Coulter, Inc.

It is a rapid POC test that detects HIV-##/ ## antibodies and free HIV-## p## antigen.

  • Point Of Care Testing
  • United States
  • Market Size
  • Alere Inc.
  • Roche Group

One stop shopping.

  • Laboratory
  • Molecular Diagnostics
  • Point Of Care Testing
  • United States
  • Market Size

One stop shopping.

  • Laboratory
  • Molecular Diagnostics
  • Point Of Care Testing
  • United States
  • Market Size

One stop shopping.

  • Laboratory
  • Molecular Diagnostics
  • Point Of Care Testing
  • United States
  • Market Size

One stop shopping.

  • Laboratory
  • Molecular Diagnostics
  • Point Of Care Testing
  • United States
  • Market Size

One stop shopping.

  • Laboratory
  • Molecular Diagnostics
  • Point Of Care Testing
  • United States
  • Market Size

One stop shopping.

  • Laboratory
  • Molecular Diagnostics
  • Point Of Care Testing
  • United States
  • Market Size

One stop shopping.

  • Laboratory
  • Molecular Diagnostics
  • Point Of Care Testing
  • United States
  • Market Size

One stop shopping.

  • Laboratory
  • Molecular Diagnostics
  • Point Of Care Testing
  • United States
  • Market Size

For instance, the Beijing Genomic Institute has the world' s largest sequencing capacity with the presence of multiple NGS systems including ## SOLiD, ## HiSeq 2000, one MiSeq, one Ion Torrent PGM, and one ## sequencer.

  • Point Of Care Testing
  • China
  • Beckman Coulter, Inc.
  • QIAGEN N.V.
  • Roche Group

Although the vast majority of infected individuals are asymptomatic carriers, HTLV infection is known to cause Adult T-cell leukemia/ lymphoma (ATLL), and HTLV-I-associated myelopathy (HAM) in some patients.

  • Point Of Care Testing
  • World
  • Alere Inc.
  • Beckman Coulter, Inc.
  • Roche Group

Hospitals are only one source of care for Vietnamese.

  • Point Of Care Testing
  • Vietnam
  • bioMerieux S.A.
  • Roche Group
  • Sysmex Corporation

To support the partnership, the Abbott Fund is providing US$## million funds over three years.

  • In Vitro Diagnostics
  • Point Of Care Testing
  • World
  • Market Size
  • Thermo Fisher Scientific, Inc.

For chronic lymphocytic leukaemia (CLL), rituximabrefractory follicular lymphoma and previously untreated advanced follicular lymphoma.

  • Diagnostics
  • Medical Device
  • Point Of Care Testing
  • United States
  • Company

One unit refers to one test.

  • Clinical Trial
  • Drug Development
  • In Vitro Diagnostic Reagent
  • Point Of Care Testing
  • Siemens Healthcare GmbH
  • SEGMENTS DEFINITION

See Figure ##-##.

  • Point Of Care Testing
  • South America
  • Alere Inc.
  • Beckman Coulter, Inc.
  • bioMerieux S.A.

One unit refers to one integrated analyzer.

  • Diagnostics
  • Drug Development
  • Point Of Care Testing
  • United States
  • Company

FOR CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL), RITUXIMAB-REFRACTORY FOLLICULAR LYMPHOMA AND PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA.

  • Point Of Care Testing
  • Germany
  • Southern Europe
  • Western Europe
  • Forecast

PCR IS USED IN LIFE SCIENCE RESEARCH LABS FOR DISEASE DIAGNOSIS (LEUKEMIA, LYMPHOMA, AND INFECTIOUS DISEASES) AS WELL AS SELECTIVE DNA ISOLATION, AMPLIFICATION, AND QUANTIFICATION, AMONG OTHER APPLICATIONS.

  • Laboratory
  • Point Of Care Testing
  • North America
  • United States
  • Market Size

The company offers products such as insti HIV-##/ HIV-## antibody test and insti HIV-##/ HIV-## test controls.

  • Clinical Trial
  • Hepatitis
  • Hepatitis Testing
  • Point Of Care Testing
  • Merck & Co., Inc.

Subsequent to the quarter, in January, the FDA approved IMBRUVICA®(ibrutinib) for the treatment of patients with marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD##based therapy.

  • Clinical Trial
  • Healthcare
  • Point Of Care Testing
  • United States
  • Pfizer Inc.

SUBSEQUENT TO THE QUARTER, IN JANUARY, THE FDA APPROVED IMBRUVICA®(IBRUTINIB) FOR THE TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD##BASED THERAPY.

  • HIV AIDS
  • Point Of Care Testing
  • Therapy
  • United States
  • Quidel Corporation